Welcome to our dedicated page for Autonomix Medical news (Ticker: AMIX), a resource for investors and traders seeking the latest updates and insights on Autonomix Medical stock.
Autonomix Medical Inc (AMIX) is a pioneer in developing catheter-based neural sensing technologies for neurological disorders. This page provides centralized access to official company announcements, regulatory updates, and breakthrough developments in microchip-enabled medical diagnostics.
Investors and industry professionals will find timely updates on AMIX's R&D milestones, strategic partnerships, and preclinical progress with its proprietary neural signal detection platform. The curated news feed ensures accurate tracking of advancements in minimally invasive neural disorder treatments.
Key updates include regulatory submissions, research collaborations, technology validations, and intellectual property developments. All content is sourced directly from company filings and authorized communications to maintain compliance and reliability.
Bookmark this page for streamlined monitoring of AMIX's progress in redefining neurological diagnostics through its microchip-integrated catheter technology. Check back regularly for verified updates on this development-stage innovator's journey toward clinical impact.
Autonomix Medical (NASDAQ: AMIX) announced the acceptance of their abstract for poster presentation at the 2025 Society of Interventional Radiology (SIR) Annual Scientific Meeting in Nashville, Tennessee, from March 29-April 2, 2025.
The presentation, titled 'Pain Mitigation in Pancreatic Adenocarcinoma: An Interim Analysis of Neurolysis via Transvascular RF Energy-Based Ablation', will be delivered by Dr. Bela Kis, Chief of Interventional Radiology at Moffitt Cancer Center, on Monday, March 31, at 12:10 PM CT.
The SIR conference, representing over 8,000 practicing interventional radiology professionals, focuses on advancing image-guided therapies and improving patient care through emerging methodologies and cutting-edge technologies.
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system diagnosis and treatment technologies, has announced its participation in the LSI USA '25 Emerging Medtech Summit.
CEO Brad Hauser will deliver a presentation on March 18, 2025, at 7:35 AM PT. The company's management team will also be available for one-on-one meetings with qualified registered investors during the conference.
Autonomix Medical (NASDAQ: AMIX) has been selected to present its catheter-based technology and initial findings from its ongoing human clinical trial in pancreatic cancer pain patients at the 2025 Cardiovascular Research Technologies (CRT) Annual Meeting. The presentation, titled 'Catheter-Based Transvascular RF Neural Ablation For Severe Pancreatic Cancer Pain: First Results From The Elpis Study,' will be delivered by Dr. Robert Schwartz, Chief Medical Officer, on March 10, 2025.
The presentation will be featured in the Innovation HUB session, which showcases innovative products and services that haven't yet been fully market-released, including early-stage/prototype, pre-clinical, first-in-human, and CE Mark technologies. The CRT Annual Meeting, scheduled for March 8-11, 2025, in Washington, DC, is a prominent educational forum focusing on new cardiovascular technology and procedures.
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in precision nerve-targeted treatments, has participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference. Brad Hauser, President and CEO, presented the company's top five reasons why investors and industry professionals should monitor Autonomix in 2025. The presentation is now available for viewing on the company's website and through a direct webcast link.
Autonomix Medical (NASDAQ: AMIX) reported Q3 FY2025 financial results and corporate updates. The company is advancing its proof-of-concept clinical trial for pancreatic cancer pain treatment, with topline data expected in 1H 2025. Key achievements include expanding intellectual property, strengthening regulatory teams, and achieving design lock for RF ablation catheter.
Financial highlights show a net loss of $2.7 million for Q3, compared to $3.1 million in the previous year. The company secured a $10 million public offering to extend its cash runway. R&D expenses increased to $1.0 million from $0.7 million year-over-year, while G&A expenses decreased to $1.7 million from $2.2 million.
The company's technology platform features a catheter-based microchip sensing array with 3,000 times greater sensitivity than current technologies. Autonomix aims for potential FDA clearance by 2027, with US clinical trials planned for 2025.
Autonomix Medical (NASDAQ: AMIX) announced the release of a new CEO Corner segment on their website. The segment features CEO Brad Hauser sharing insights from the 43rd Annual J.P. Morgan Healthcare Conference and reviewing recent industry news. Autonomix is a medical device company developing technologies for diagnosing and treating nervous system diseases.
Autonomix Medical (NASDAQ: AMIX) has achieved a important milestone by finalizing the design ('design lock') of its Application Specific Integrated Circuits (ASIC) microchip following successful in vivo preclinical and bench testing. The company has initiated manufacturing of the ASIC microchip for human use and is progressing toward submitting an Investigational Device Exemption (IDE).
The ASIC microchip is central to Autonomix's intellectual property portfolio, enabling the detection of nerve signals through vasculature. The company plans to commence a pivotal clinical trial in 2025 to support a De Novo application for FDA approval. The technology aims to commercialize the Autonomix Sensing and RF Ablation System for treating pancreatic cancer pain in the United States.
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system disease diagnosis and treatment technologies, has announced its participation in the Virtual Investor Closing Bell Series scheduled for Wednesday, January 22, 2025, at 4:00 PM ET.
During the event, CEO Brad Hauser will deliver a corporate overview and business outlook. The format includes a moderated discussion with a live Q&A session where investors can submit questions. The company will address as many queries as time permits.
The presentation will be accessible through a live video webcast on the Events page in the Investors section of autonomix.com. A replay will be available two hours after the live event and remain accessible for 90 days.
Autonomix Medical (NASDAQ: AMIX) announced the acceptance of its abstract for poster presentation at the Society of Interventional Oncology (SIO) 2025 Annual Scientific Meeting, scheduled for January 30 – February 3, 2025, in Las Vegas. The abstract, titled 'Ablation of the Celiac Ganglia for Treatment of Pancreatic Cancer Pain: An Interim Analysis of the First Five Lead-In Patients,' will be presented by the company's Chief Medical Officer, Dr. Rob Schwartz.
The presentation at SIO, a non-profit organization focused on advancing interventional oncology as a key cancer therapy approach, represents an opportunity to showcase the company's progress in developing treatments for diseases involving the nervous system.
Autonomix Medical (NASDAQ: AMIX) has been granted U.S. patent 12,064,256 covering technology for treating cancerous tumors and cancer-related pain. The company's growing patent portfolio includes over 80 issued patents and 40+ pending applications. A preclinical mouse study showed statistically significant reductions in both metastases and tumor mass through targeted nerve ablation.
The company's proprietary catheter-based technology features a microchip sensing array antenna with up to 3,000 times greater sensitivity than current technologies. Initially focusing on pancreatic cancer-related pain, Autonomix's platform combines nerve detection and RF ablation capabilities for precise treatment. The company is currently conducting a proof-of-concept human clinical trial focused on pain reduction.
FAQ
What is the current stock price of Autonomix Medical (AMIX)?
What is the market cap of Autonomix Medical (AMIX)?
